Pharmaceutical - Markets & Marketing, USA

Filter

Current filters:

Markets & MarketingUSA

Popular Filters

1 to 25 of 71 results

Afaxys announces wider US availability of ella emergency contraceptive

12-11-2014

US drugmaker Afaxys Pharmaceuticals, a division of Afaxys Inc, has announced wider US availability of…

AfaxysellaHRA PharmaMarkets & MarketingPharmaceuticalReproductiveUSAWomen's Health

Biologics will complement statins in cholesterol treatment space, says GlobalData

Biologics will complement statins in cholesterol treatment space, says GlobalData

11-11-2014

Biologics will play an influential role in shaping the future of cardiovascular drug treatment, in particular…

alirocumabAmgenCardio-vascularevolocumabMarkets & MarketingPharmaceuticalRegeneronSanofiUSA

Pharming and Salix's Ruconest launches in the USA for hereditary angioedema

Pharming and Salix's Ruconest launches in the USA for hereditary angioedema

03-11-2014

Pharming Group and Salix Pharmaceuticals have launched Ruconest (C1 esterase inhibitor) in the USA for…

Cardio-vascularMarkets & MarketingPharmaceuticalPharming Group NVRuconestSalixUSA

Most-used agents in US bipolar disorder treatment sector; report

Most-used agents in US bipolar disorder treatment sector; report

24-10-2014

Through analysis of US longitudinal patient-level claims data, Bristol-Myers Squibb and Otsuka’s Abilify…

AbilifyBristol-Myers SquibbCymbaltaDainippon Sumitomo PharmaEli LillyGlaxoSmithKlineLamotrigineLatudaMarkets & MarketingNeurologicalOtsukaPharmaceuticalUSA

Orexigen earns total $100 million milestone on Contrave

Orexigen earns total $100 million milestone on Contrave

15-10-2014

US biopharma company Orexigen Therapeutics says it has earned a $70 million milestone payment from partner…

ContraveFinancialMarkets & MarketingMetabolicsOrexigen TherapeuticsPharmaceuticalTakeda PharmaceuticalUSA

Report: HER2-positive breast cancer market could treble in USA by 2023

Report: HER2-positive breast cancer market could treble in USA by 2023

02-10-2014

The US treatment market for human epidermal growth factor receptor type 2 (HER2)-positive breast cancer…

HerceptinMarkets & MarketingOncologyPharmaceuticalRocheUSA

Merck's entry into allergic rhinitis market will send total market value soaring by 2018, says GlobalData

Merck's entry into allergic rhinitis market will send total market value soaring by 2018, says GlobalData

30-09-2014

The US market for treatments of allergic rhinitis is set to see its value increase fourfold by 2018,…

GlobalDataGrastekMarkets & MarketingMerck & CoOralairPharmaceuticalRagwitekRespiratory and PulmonarySingulairUSA

Achillion a good candidate for collaboration or takeover based on hepatitis C candidate, says Edison

Achillion a good candidate for collaboration or takeover based on hepatitis C candidate, says Edison

29-09-2014

Achillion Pharmaceuticals is in a prime position to develop its own all-oral hepatitis C treatment as…

Achillion PharmaceuticalsFinancialMarkets & MarketingNephrology and HepatologyPharmaceuticalUSA

Decline in sales rep access makes digital communications vital, says ZS report

Decline in sales rep access makes digital communications vital, says ZS report

24-09-2014

Digital communication channels are becoming increasingly important as cost pressures mean drug reps reduce…

BusinessMarkets & MarketingPharmaceuticalResearchUnited StatesUSA

Rheumatoid arthritis drug market will grow to $18.2 billion in 2023, report

17-09-2014

The rheumatoid arthritis (RA) disease-modifying antirheumatic drug market will increase from $14 billion…

Anti-Arthritics/RheumaticsbaricitinibBiosimilarsEli LillyEuropeIncyteJapanMarkets & MarketingPfizerPharmaceuticalUSAVertexXeljanz

Lundbeck launches Northera in USA

Lundbeck launches Northera in USA

02-09-2014

Danish CNS specialist Lundbeck said today that Northera (droxidopa) capsules for oral use are now available…

Chelsea TherapeuticsLundbeckMarkets & MarketingNeurologicalNortheraPharmaceuticalUSA

Colorectal cancer market will remain steady at $7.7 billion by 2023; report

29-08-2014

The market for colorectal cancer (CRC) therapies will remain constant, at around $7.7 billion by 2023…

EuropeJapanMarkets & MarketingOncologyPharmaceuticalUSA

Globavir to seek approval and launch of novel Ebola treatment by year-end

Globavir to seek approval and launch of novel Ebola treatment by year-end

19-08-2014

Privately-held US biotech firm Globavir Biosciences said yesterday that it intends to develop its lead…

Antibiotics and Infectious diseasesGBV006Globavir BiosciencesMarkets & MarketingPharmaceuticalRegulationRest of the WorldTropical diseasesUSA

Belsomra could become first-line insomnia therapy, says GlobalData

Belsomra could become first-line insomnia therapy, says GlobalData

18-08-2014

Insomnia treatment Belsomra (suvorexant) from US pharma giant Merck & Co has the potential to become…

BelsomraChemistryCyclopyrrolonesInsomniaMarkets & MarketingMerck & CoNeurologicalOrganic chemistryPharmaceuticalUSA

Turkish man pleads guilty to importing illegal cancer drugs into USA

Turkish man pleads guilty to importing illegal cancer drugs into USA

17-08-2014

Sabahaddin Akman, owner of the Istanbul, Turkey, firm Ozay Pharmaceuticals, has pleaded guilty to charges…

AvastinLegalMarkets & MarketingOncologyOzay PharmaceuticalsPharmaceuticalRituxanSabahaddin AkmanTurkeyUSA

MS market to reach $20 billion in 2023 boosted by five new therapies

MS market to reach $20 billion in 2023 boosted by five new therapies

08-08-2014

The forecast launch of five immunomodulatory therapies for relapsing forms of multiple sclerosis will…

CNS DiseasesEuropeImmunosuppressantsJapanMarkets & MarketingMSPharmaceuticalUSA

Nicox and Bausch + Lomb to co-promote latanoprostene bunod for glaucoma

Nicox and Bausch + Lomb to co-promote latanoprostene bunod for glaucoma

08-08-2014

International opthalmic company Nicox is to co-promote latanoprostene bunod with Bausch + Lomb, the eyecare…

Bausch & LombCanadaGlaucomaLatanoprost OphthalmicMarkets & MarketingNicOxOphthalmicsOpticsPharmaceuticalUSA

Aeterna Zentaris and Ascend Therapeutics team up to market each other's products

Aeterna Zentaris and Ascend Therapeutics team up to market each other's products

05-08-2014

Quebec-based biopharma drug developer Aeterna Zentaris has said it is to collaborate with women’s healthcare…

AEterna ZentarisAscend PharmaClinical researchDavid DoddEstroGelHealthcare specialistMarkets & MarketingPharmaceuticalPharmaceutical sciencesUSAWomen's Health

1 to 25 of 71 results

Back to top